Announcement • Jul 08
ALZAI Health Corp. Validates AI-Driven Alzheimer’s Disease Risk Screening Solution On Large-Scale U.S. Patient Data ALZAI Health Corp. announced the validation of its proprietary artificial intelligence-driven Alzheimer's disease risk identification models using a large-scale U.S. longitudinal healthcare dataset, representing a significant milestone in the Company's potential U.S. commercialization. The validation demonstrated that ALZAI's risk-stratification models achieved performance on-par with previous validation studies conducted using Israeli healthcare data. The validation utilized real-world longitudinal healthcare data on more than 1,100,000 U.S. patients. The dataset contained approximately 38,000,000 common blood chemistry laboratory test results and over 3,000,000 standard chronic disease diagnostic records collected through routine care representing over 100,000,000 clinical data points. The U.S. healthcare dataset was licensed from HealthVerity and was used to evaluate ALZAI's proprietary artificial intelligence solution across multiple prediction horizons and varying lengths of longitudinal patient history. The validation included blood-test-only, chronic disease diagnoses-only, and combined blood-test-data-and-chronic-disease-diagnoses models. ALZAI utilizes ubiquitous and routine clinical information and basic patient demographics in order to deliver a population-level risk screening solution. HealthVerity did not participate in the development of ALZAI's artificial intelligence models, the validation methodology, the analysis of results, or the conclusions presented by the Company and did not verify, endorse or independently validate the Company's results or conclusions. The validation was based on a licensed historical real-world dataset and specific model assumptions and methodologies, and results may not be replicated in prospective studies, other datasets, other patient populations or real-world clinical implementation. The validation supports the scalability of ALZAI's Solution across multiple healthcare environments and represents an important milestone as the Company moves towards potential commercialization within the United States. ALZAI's solution is intended to support disease risk identification and is not intended to diagnose Alzheimer's disease or replace clinical judgment. Announcement • Jun 10
Alzai Health Corp. has completed an IPO in the amount of CAD 4 million. Alzai Health Corp. has completed an IPO in the amount of CAD 4 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 10,000,000
Price\Range: CAD 0.4 Board Change • Jun 08
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Faizaan Lalani was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
